Position in GRFS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$189,276
-$236,104 QoQ
Shares Held
26,734
-49.6% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#77
of 164 holders
Holding Since
Sep 2023
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026SYON CAPITAL LLC holds $48,543,750 across 15 Drug Manufacturers - General names. GRFS ranks #15 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
13,135 | $15,754,514 | |
| 2 | JNJ |
Johnson & Johnson
|
32,155 | $8,166,405 | |
| 3 | ABBV |
AbbVie Inc.
|
27,228 | $6,851,653 | |
| 4 | MRK |
Merck & Co., Inc.
|
29,362 | $3,773,017 | |
| 5 | AMGN |
Amgen Inc
|
8,459 | $3,063,173 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
20,463 | $2,585,295 | |
| 7 | AZN |
Astrazeneca PLC
|
12,068 | $2,288,334 | |
| 8 | GSK |
GSK plc
|
29,588 | $1,551,002 |
All Filings in GRFS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $189,276 | 26,734 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $425,380 | 53,040 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $438,730 | 46,923 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $427,552 | 42,927 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $365,487 | 40,430 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $136,817 | 19,243 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $196,996 | 26,478 | Shares | Sole | 2025-02-14 | |
| 2023-12-31 | $243,592 | 21,072 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $249,759 | 27,326 | Shares | Sole | 2023-11-03 | |
| No filing history on record for this holder in this stock. | ||||||